Showing 1791-1800 of 5603 results for "".
Optimizing Patient Management Strategies
https://reachmd.com/programs/cme/optimizing-patient-management-strategies/35882/Learn about LGMD2I/R9—genetics, diagnosis, treatment, clinical trials, and care gaps—in this expert-led, comprehensive educational video series.Establishing Our Foundation of LGMD2I/R9
https://reachmd.com/programs/cme/establishing-our-foundation-of-lgmd2ir9/35588/Learn about LGMD2I/R9—genetics, diagnosis, treatment, clinical trials, and care gaps—in this expert-led, comprehensive educational video series.Epilepsy: Beyond Seizure Impact
https://reachmd.com/programs/cme/epilepsy-beyond-seizure-impact/35794/Tune in to learn about using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) & treatment-resistant depression (TRD).Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
https://reachmd.com/programs/project-oncology/ctdna-muscle-invasive-bladder-cancer-niagara-data/36310/Could emerging biomarkers redefine how we assess response and recurrence risk in muscle-invasive bladder cancer? To find out, Dr. Charles Turck speaks with Dr. Petros Grivas about the key findings from the phase 3 NIAGARA trial. Together, they explore how perioperative durvalumab impacts circulatingOral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
https://reachmd.com/programs/cme/tbd/37671/Learn from a multidisciplinary faculty panel how to Improve outcomes for patients with CKD and HFrEF using optimal RAASi and MRAs while managing hyperkalemia with potassium binders.Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
https://reachmd.com/programs/cme/translating-the-latest-kdigo-guidelines-into-practice-iv-iron-therapy-in-patients-with-nondialysis-dependent-ckd/54631/Join Drs. Núñez and Rossignol for a case-based discussion highlighting the most recent updates to the KDIGO guidelines for the management of anemia in CKD.Adjuvant Nivolumab in High-Risk Muscle Invasive Urothelial Carcinoma: 5-Year Data
https://reachmd.com/programs/project-oncology/adjuvant-nivolumab-in-high-risk-muscle-invasive-urothelial-carcinoma/36306/Five years after treatment, the impact of adjuvant nivolumab still holds strong in high-risk muscle invasive urothelial carcinoma. Join Drs. Brian McDonough and Matthew Galsky as they review the CheckMate 274 trial’s long-term data, which show sustained disease-free survival and highlight ctDNA’s poFrom Diagnosis to Prognosis: Using MyPath® Melanoma and DecisionDx®-Melanoma to Help Guide Patient Management Decisions
https://reachmd.com/programs/practical-dermatology/from-diagnosis-to-prognosis-using-mypath-melanoma-and-decisiondx-melanoma-to-help-guide-patient-management-decisions/39944/Gene Expression Profile Testing Helps Clinicians Clarify Diagnostically Ambiguous Lesions and Deliver Personalized, Risk-Aligned Melanoma CarePI3K Pathway Inhibitors: Safety and Tolerability Profiles
https://reachmd.com/programs/cme/PI3K-Pathway-Inhibitors-Safety-and-Tolerability-Profiles/37338/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity
https://reachmd.com/programs/cme/beyond-the-horizon-in-multiple-myeloma-harnessing-novel-celmod-mechanisms-for-increased-antimyeloma-activity/35916/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity